Pranlukast is a novel small molecule activator of the two-pore domain potassium channel TREK2

Autor: Lewis Byrom, Jeff Jerman, Egle Gaurilcikaite, Alistair Mathie, Paul D. Wright, David McCoull, Jonathan M. Large, Barbara W. Hadrys, Yvonne Walsh, Emma L. Veale

Publikováno v: Biochemical and Biophysical Research Communications. 520:35-40

TREK2 (KCNK10, K2P10.1) is a two-pore domain potassium (K2P) channel and a potential target for the treatment of pain. Like the majority of the K2P superfamily, there is currently a lack of useful pharmacological tools to study TREK2. Here we present

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::162e9e2b1e010dc8a05809a0b03da63e
https://doi.org/10.1016/j.bbrc.2019.09.093

Dimethylarginine dimethylaminohydrolase 1 is involved in spinal nociceptive plasticity

Autor: Sophie Pezet, Anthony H. Dickenson, James Leiper, Claire A. Sand, Stephen B. McMahon, Manasi Nandi, Egle Gaurilcikaite, Richard DʼMello

Publikováno v: PAIN
PAIN, Elsevier, 2015, 156 (10), pp.2052-2060. ⟨10.1097/j.pain.0000000000000269⟩
PAIN, 2015, 156 (10), pp.2052-2060. ⟨10.1097/j.pain.0000000000000269⟩
Pain

Supplemental Digital Content is Available in the Text. Inhibition of dimethylarginine dimethylaminohydrolase 1 attenuates pain-related behavior and hyperexcitability in pain conditions associated with excessive nitric oxide production, representing a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06768edaccef27cb045ab1a18fe098b1
https://hal.archives-ouvertes.fr/hal-03242246